Sham Mailankody, MBBS, on Updates on ALLO-715 CAR T in R/R Multiple Myeloma

“There were a few patients who had more serious infections, including a couple of patients who had, unfortunately, fatal complications from the treatment. The good news is, since our last update last year, there's no more patients who have developed serious infections. And this is something that we think can be further defined by using more appropriate infection prophylaxis monitoring strategies to further lower the risk of infections.”

The allogeneic anti-BCMA chimeric antigen receptor (CAR) T-cell therapy ALLO-715 had a manageable safety profile with an objective response rate of 65% and a very good partial response rate of about 50% in patients with relapsed/refractory multiple myeloma in the phase 1 UNIVERSAL open-label trial (NCT04093596). These updated data were presented at the 64th American Society of Hematology (ASH) Annual Meeting, held December 10-12, 2022, in New Orleans, Louisiana, by Sham Mailankody, MBBS, associate attending physician, Memorial Sloan Kettering Cancer Center.

CGTLive spoke with Mailankody to learn more aboutALLO-715, including genome edits made with Allogene’s TALEN platform to lower rates of graft-vs-host disease and to allow for better expansion of donor T cells. He discussed the new safety and efficacy data presented at the meeting, including clinically meaningful data seen in participants treated at dose level 3.

Click here to read more coverage of the ASH 2022 meeting,

REFERENCE

2019 Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma. Presented at: 64th ASH Annual Meeting, December 10-12, 2022, in New Orleans, Louisiana. Abstract #2019.